Please login to the form below

Not currently logged in
Email:
Password:

Prevymis

This page shows the latest Prevymis news and features for those working in and with pharma, biotech and healthcare.

EC grants MSD’s Prevymis orphan product designation

EC grants MSD’s Prevymis orphan product designation

The status for Prevymis’ (letermovir) covers the prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). ... Around the same time, Prevymis also

Latest news

  • CHMP backs MSD’s CMV infection treatment CHMP backs MSD’s CMV infection treatment

    Merck Sharp &Dohme (MSD) is closing on European approval for its infection treatment Prevymis (letermovir) after it received backing from the Committee for Medicinal Products for Human Use’s (CHMP) last ... week. Prevymis is one of a new class of

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics